Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells $21,612.00 in Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 600 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $36.02, for a total value of $21,612.00. Following the completion of the transaction, the chief financial officer directly owned 88,240 shares in the company, valued at $3,178,404.80. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Tuesday, July 7th, Christine Mikail Cvijic sold 4,200 shares of Neurogene stock. The shares were sold at an average price of $36.13, for a total value of $151,746.00.
• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The stock was sold at an average price of $34.82, for a total value of $141,404.02.
• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The stock was sold at an average price of $34.06, for a total value of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total value of $300,000.00.

Neurogene Stock Performance

Shares of NGNE opened at $42.84 on Friday. The firm has a market cap of $676.96 million, a PE ratio of -9.42 and a beta of 1.68. Neurogene Inc. has a 52-week low of $15.93 and a 52-week high of $43.66. The business’s 50 day moving average price is $30.23 and its two-hundred day moving average price is $23.86.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.09). Research analysts predict that Neurogene Inc. will post -5.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. UBS Group set a $70.00 price target on shares of Neurogene in a report on Wednesday, June 3rd. Canaccord Genuity Group dropped their price objective on shares of Neurogene to $180.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Rodman & Renshaw initiated coverage on Neurogene in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Neurogene in a research note on Tuesday, June 9th. Finally, Guggenheim started coverage on Neurogene in a research report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $84.83.

Institutional Investors Weigh In On Neurogene

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its holdings in shares of Neurogene by 210.0% in the 1st quarter. Renaissance Technologies LLC now owns 43,400 shares of the company’s stock worth $875,000 after acquiring an additional 29,400 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Neurogene by 12.8% during the 1st quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock worth $525,000 after purchasing an additional 2,950 shares in the last quarter. Virtus Investment Advisers LLC increased its holdings in Neurogene by 128.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 12,716 shares of the company’s stock worth $262,000 after purchasing an additional 7,138 shares in the last quarter. Logos Global Management LP purchased a new stake in shares of Neurogene in the fourth quarter worth approximately $4,017,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Neurogene in the fourth quarter valued at approximately $575,000. 52.37% of the stock is owned by institutional investors.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.